周围剂量当量仪的研制

周围剂量当量仪研制是根据国际辐射单位和测量委员会（ＩＣＲＵ）３９号报告推荐的周围剂量当量而设计的一种数字化智能型辐射防护仪。方法采用能量补偿对探测器进行能响校正。结果补偿结果使得探测器在４７～２３０ｋｅＶ与ＩＳＯ推荐的Ｈ＊（１０）／Ｋａ值误差在５％以内。本文重点描述了周围剂量当量仪探测器部分的工艺结构和剂量学性能以及电子学测量部分的主要功能。结论通过实际应用我们初步获得的结论是由于该仪器可直接测量周围剂量当量，稳定性好且具有自动取平均值特点，它可做为实验室校准用测量仪器，又由于该仪器体积小，电池供电，读数面板又有背光功能，它也可以做为现场仪器用于辐射防护实践的现场测量     

Conventional MRA and contrast- enhanced MRA of extracranial vessel segments

Summary The introduction of fast gradient systems allows a reliable visualization of the extracranial carotid vessels by the magnetic resonance angiography (MRA) which meanwhile is implemented into clinical routine. By the mainly applied time-of-flight (TOF) technique, vessels can be imaged without contrast agent (CA). Due to the application of ultra-fast gradient-echo-sequences, the first-pass evaluation of an intravenous bolus-injection of Gadolinium in the carotids from the aortic arch up to the skull base can be performed in less than 30 s. In this study, advantages and disadvantages of both techniques are discussed. For a qualitatively optimal contrast enhanced MRA (CE-MRA) timing parameters like injection delay, flow rate and the adjustment of sequence parameters have to be considered in relation to the fast venous return from the sinus to the jugular veins. First, the optimal time point of the data acquisition have been determined at a model and with a computer simulation in reference to the presence of CA in the arteries. As a result, 90 % of the contrast contribution is defined by 16 % of the symmetrically acquired central k-space lines. A measuring protocol for clinical use was obtained by a gradual variation of spacial resolution, measuring time and CA-injection parameters and was proved in normal volunteers and patients. An exact determination of the bolus-arrival-time by means of a test-bolus injection was acquired. The best qualitative results were achieved by a double-dose injection at 2 ml/s injection rate. The temporal reserves of ultra-fast sequences should be invested in the improvement of the spatial resolution. To date, further investigations related to the problem of optimal CA-application may improve the potentials of CE-MRA procedures.      

肺结核线索调查中X线胸透的代价和效益试评

用热释光剂量计测试了受检者胸透体表照射量，结果表明受检者体表照射量符合对数正态分布，几何均值为０．１９ｍＣ·ｋｇ－１，高于一般体检胸透照射量水平。根据危险度系数，估算出由此造成的辐射诱发恶性肿瘤危险度，男女分别为３．５５×１０－６和４．０５×１０－６，后裔遗传疾患的危险度均为４．０×１０－８，由此估计该次实践造成的人均寿命缩短时间为０．５２ｈ·人－１。利用江苏省结核病的患病率、死亡率、化疗治愈率估算出由此次实践带来的人均寿命延长时间为４５．８ｈ·人－１。     

基因定量检测方法研究进展

基因定量检测已经成为研究基因组变异以及由于基因重组所引起的相关疾病的重要手段。大片段的基因组的重复和缺失可以引起致病突变。使用PCR和测序等定性检测方法很难探测到杂合状态的缺失和重复,因此探寻高效、可靠、灵敏的基因定量检测方法是当务之急。在过去的几年中已经相继出现了一些自动高效的技术方法。现在可用的基因定量方法大致可以分成3类:DNA印迹技术,细胞遗传学方法和以PCR扩增为基础的定量。本文对基因定量的最新进展作一综述,探讨其优缺点以期对定量研究方法的选择有所帮助。     

131Ⅰ治疗Graves病剂量探讨

目的　探讨1 31 Ⅰ治疗Graves病时 ,不同的剂量计算方法与治愈率以及治疗后并发症的关系。方法　在计算治疗Graves病所需1 31 Ⅰ时 ,分别采取不同的两种计算方法 ,观察两者治愈率及并发症的发生情况 ,并做多因素对比分析。结果　治疗组较对照组 1次治愈率提高约 12 % ,近期甲状腺功能减退延续为永久性甲状腺功能减退者亦明显减少 ,治疗效果明显优于后者。结论　1 31 Ⅰ治疗剂量计算时 ,既要有公式的规范性 ,又要有根据具体情况调节的灵活性 ,即可明显提高治疗效果     

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

: A rising prostate specific antigen (PSA) following treatment for adenocarcinoma of the prostate indicates eventual clinical failure, but the rate of rise can be quite different from patient to patient, as can the pattern of clinical failure. We sought to determine whether the rate of PSA rise could differentiate future local versus metastatistic failure.

: Two thousand six hundred sixty-seven PSA values from 400 patients treated with radiotherapy for localized adenocarcinoma of the prostate were analyzed with respect to PSA patterns and clinical outcome. Patients had received no hormonal therapy or prostate surgey and had ?4 PSA values post-treatment PSA rate of rise, determined by the slope of the natural log, was classified as gradual (< 0.69 log (ng/ml)/year, or doubling time (DT) > 1 year), moderate (0.69-1.4 log (ng/ml)/year, or DT 6 months-1 year), or rapid [>1.4 log (ng/ml)/year, or DT < 6 months].

: SIxty-one percent of patients had non-rising PSA following treatment; 25% of patients with rising PSA developed clinical failure, and 93% of patients with clinical failure had rising PSA. The rate of rise discerned different clinical failure patterns. Local failure occurred in 23% of patients with moderate rate of rise versus 7% with gradual rise (p = 0.0001). Metastatic disease developed in 46% of those with rapid versus 8% with moderate rise (p < 0.0001). By multivariate analysis, in addition to rate of rise, PSA nadir and rate of decline predicted local failure; those with post-treatment nadir of 1–4 ng/ml were five times more likely to experience local failure than nadir < 1 ng/ml (p = 0.0002). Rapid rate of rise was the most significant independent predictor of metastastic failure.

: The rate of PSA rise following definitive radiotherapy can predict clinical failure patterns, with a rapidly rising PSA indicating metastatic recurrence and moderately rising PSA local recurrence. This information could potentially dirent therapy; if the rise predicts metastatic failure hormonal therapy could be cosidereed, while aggressive salvage therapy may benefit subclinical local recurrence identified by a moderate rate of PSA rise.     

The effect of radiation on the fracture repair process. A biomechanical evaluation of a closed fracture in a rat model

The effects of a single dose of irradiation on the biomechanical parameters of the fracture healing process were studied in a rat model. Intramedullary pinning was performed before production of a closed femoral midshaft fracture. The experimental group was exposed to 900 rad 3 days after fracture and was compared with a control group with a similar fracture that received no irradiation. Animals were killed at intervals ranging from 2-16 weeks after surgery and the bones were tested until failure in torsion. In the irradiated groups, a delay of 4 weeks was noted in the biomechanical parameters associated with fracture healing (torque to failure, torsional stiffness, angle to failure, and biomechanical stage). Despite this delay in the normal temporal progression, the staging and stiffness approached normal controls within an 8-week period. However, the torque to failure remained below normal levels at the conclusion of this study. These results differ from a previous study using an open fracture model.     

放射线照射对体外培养的骨巨细胞瘤细胞作用的实验研究

目的 :对体外培养的骨巨细胞瘤细胞进行放射线照射 ,并观察其效应。方法 :对 6例经临床、X线和病理组织学检查证实的骨巨细胞瘤标本进行体外细胞培养 ,传代后实验组进行放射线照射处理 ,对照组未进行放射线处理。分别采用倒置显微镜观察、台盼蓝染色后计数、MTT法测定和FCM分析来观察放射线照射对体外培养的骨巨细胞瘤细胞的细胞毒性和细胞周期的影响。结果 :放射线照射后 ,体外培养的骨巨细胞瘤细胞可见逐渐发生皱缩和脱落 ,细胞存活率为 8 2 7%～ 13 5 0 % ,细胞毒性指数为 83 19% ,FCM分析显示G0与G1期比例明显增加 ,G2与M期比例明显减少。结论 :放射线照射对体外培养的骨巨细胞瘤细胞有较强的细胞毒性作用     

血小板第4因子对辐射损伤小鼠免疫功能的保护作用

目的：探讨血小板第4因子（plateletfactor4，PF4）对辐射损伤小鼠免疫系统的影响。方法：雄性BALB／c小鼠随机分为3组，第1组（单纯照射组）、第Ⅱ组（PF4保护组）、第Ⅲ组（正常对照组），第Ⅱ组在照射前26h及20h腹腔注射PF440μg／kg，全身一次性5Gy60Co—γ射线照射后瑞氏染色法计数外周血淋巴细胞百分数。胸腺、脾脏制成细胞悬液计数后，MTT比色法测定胸腺及脾细胞增殖能力。结果：第Ⅱ组小鼠外周血淋巴细胞百分数下降趋势较第1组明显减慢。胸腺、脾细胞计数，第Ⅱ组明显高于第1组。淋巴细胞增殖试验，第Ⅱ组与第1组相比，小鼠胸腺及脾细胞的增殖能力明显增强。结论：PF4对免疫系统有辐射保护作用，可明显增强辐射损伤小鼠的免疫功能。     

太钢1998～2002年放射工作人员个人剂量监测分析

目的为进一步调查太钢放射工作人员外照射剂量大小，以评价太钢近几年来放射管理和放射防护效果，降低放射危害，保护放射工作人员身体健康。方法根据GB5294-85《放射工作人员个人剂量监测方法》将1998-2002年在太钢从事放射的工作人员分为4组：医用X射线、工业X射线、工业γ射线和医用同位素组，进行外照射个人剂量监测，并计算1998-2002年各年度平均年剂量当量。每年监测4个周期，每个周期为3个月，并对监测结果进行分析。结果①5个年度平均年剂量当量为1．46mSv，1998年最高，从2000年起有逐渐下降的趋势；并且除2002年与2000、2001年比较，U检验差异无统计学意义外，其余各年度之间比较，差异均有统计学意义（P〈0．01）；②1998-2002年各工种之间年个人剂量当量监测结果，以工业γ射线组均值最低，医用X射线组最高。U检验，工业γ射线组与其他3个组比较，差异有统计学意义（P〈0．01），医用X射线组与工业X射线组比较，差异亦有统计学意义；③1998-2002年各年度年个人有效剂量频数分组分布，〈1mSv／a组占受检总数的27.11％，〉5mSv／a的占0．31％，〈5mSv／a的占99．69％。经χ^2检验，各年度之间比较，差异有统计学意义（χ^2=377．33，P〈0．01）；④各工种个人剂量当量分组频数分布情况：〈1mSv／a占受检总数的26．49％，1-2mSv／a组占59．89％．2-3mSv／a占10．52％，〈5mSv／a的占99．69％，〉5mSv／a仅3例，为医用X线组。各工种之间比较，χ^2检验有统计学意义（χ^2=1030．79，P〈0．001）。结论1998-2002年平均剂量当量远低于国家标准，并逐年下降，说明近5年太钢加强放射工作人员的健康和防护设施管理的工作，放射工作环境是安全的。